Cellebrite DI Ltd. (NASDAQ:CLBT) Short Interest Update

Cellebrite DI Ltd. (NASDAQ:CLBT - Get Free Report) saw a significant decline in short interest during the month of May. As of May 31st, there was short interest totalling 1,070,000 shares, a decline of 40.9% from the May 15th total of 1,810,000 shares. Currently, 1.0% of the company's stock are sold short. Based on an average daily volume of 1,260,000 shares, the short-interest ratio is presently 0.8 days.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in CLBT. Assetmark Inc. bought a new stake in Cellebrite DI during the first quarter worth approximately $33,000. Catalyst Capital Advisors LLC purchased a new stake in shares of Cellebrite DI in the first quarter valued at $51,000. Virtus Advisers LLC purchased a new stake in shares of Cellebrite DI in the first quarter worth approximately $63,000. Gen Wealth Partners Inc purchased a new position in Cellebrite DI in the fourth quarter valued at about $85,000. Finally, NewEdge Advisors LLC boosted its stake in shares of Cellebrite DI by 600.7% during the 4th quarter. NewEdge Advisors LLC now owns 3,910 shares of the company's stock worth $86,000 after acquiring an additional 3,352 shares in the last quarter. 45.88% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on CLBT shares. Needham & Company LLC reaffirmed a "buy" rating and issued a $24.00 price target on shares of Cellebrite DI in a report on Friday, June 6th. JPMorgan Chase & Co. decreased their price objective on Cellebrite DI from $29.00 to $25.00 and set an "overweight" rating on the stock in a report on Monday, May 12th. Seven research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Cellebrite DI has an average rating of "Buy" and a consensus target price of $22.43.

Cellebrite DI Trading Up 1.0%

Shares of NASDAQ CLBT traded up $0.15 during midday trading on Monday, reaching $15.93. 1,547,682 shares of the stock were exchanged, compared to its average volume of 1,476,216. Cellebrite DI has a 52-week low of $11.47 and a 52-week high of $26.30. The company has a market capitalization of $3.81 billion, a P/E ratio of -11.46, a P/E/G ratio of 4.27 and a beta of 1.32. The stock has a 50 day moving average price of $18.14 and a 200-day moving average price of $19.95.

Cellebrite DI (NASDAQ:CLBT - Get Free Report) last issued its quarterly earnings data on Wednesday, May 14th. The company reported $0.10 EPS for the quarter, topping analysts' consensus estimates of $0.09 by $0.01. Cellebrite DI had a positive return on equity of 58.70% and a negative net margin of 70.54%. The company had revenue of $107.55 million for the quarter, compared to analysts' expectations of $109.36 million. During the same quarter in the previous year, the firm posted $0.08 earnings per share. The firm's quarterly revenue was up 20.0% on a year-over-year basis. On average, analysts forecast that Cellebrite DI will post 0.3 earnings per share for the current year.

Cellebrite DI Company Profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.